POS0035 INFLUENCE OF INTERSTITIAL LUNG DISEASE DURATION ON THE TREATMENT OF RHEUMATOID ARTHRITIS-INTERSTITIAL LUNG DISEASE. NATIONAL MULTICENTER STUDY OF 392 PATIENTS WITH ABATACEPT
Authors: A. Serrano-Combarro, B. Atienza-Mateo, N. Del-Val, L. Ibarrola Paino, I. Casafont-Solé, R. Melero, A. Pérez Linaza, I. Serrano-García, S. Castañeda, R. Ortega Castro, J. Calvo Gutierrez, N. Mena-Vázquez, N. Vegas-Revenga, L. Domínguez Casas, C. Delgado-Beltran, C. Díez, T. Pérez Sandoval, M. Retuerto-Guerrero, L. Pérez Albaladejo, R. López-Sánchez, M. G. Mazano, A. Brandy-Garcia, P. López Viejo, G. Bonilla, O. Maiz, M. D. C. Carrasco Cubero, M. Garijo Bufort, M. Moreno, A. Urruticoechea-Arana, S. Ordoñez, C. González-Montagut Gómez, C. Peralta-Ginés, M. C. Osorio, E. Cañadillas, J. R. De Dios Jiménez de Aberásturi, F. Lozano Morillo, T. Vazquez Rodriguez, P. Carreira, J. M. Blanco, C. Fernández-Díaz, J. Loricera, I. Ferraz-Amaro, D. Ferrer, R. Blanco
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Interstitial lung disease (ILD) is a severe complication of rheumatoid arthritis (RA). Abatacept (ABA) has demonstrated efficacy in the treatment of RA-ILD, especially if it is initiated early during the ILD <b>[1-2].</b> <h3>Objectives</h3> To compare the efficacy of ABA in RA-ILD patients according to ILD duration. <h3>Methods</h3> National multicenter study of 392 RA-ILD patients treated with ABA. Patients with ABA initiation early in the disease (during the first 6 months since ILD diagnosis) were compared to those in whom ABA was started after 2 years of ILD diagnosis ("early" vs "late" group, respectively). We analyzed in the 2 groups the following outcomes: a) forced vital capacity (FVC), b) diffusing capacity of the lungs for carbon monoxide (DLCO), c) chest high resolution computed tomography (HRCT), d) dyspnea and e) arthritis activity. <h3>Results</h3> A total of 157 patients were included in the "early" group and 135 patients in the "late" group. Baseline demographic and clinical characteristics are shown in Table 1. Mean baseline values of FVC were significantly higher in the "early" group. The evolution of FVC and DLCO for 48 months is shown in Figure 1. Both parameters remained stable during 12 months of ABA therapy, with no statistically significant differences found (although lower stable values of FVC in the "late" group). Available chest HRCT images improved/stabilized in 75% and 51% of patients in the "early" and "late" group, respectively. Stabilization or improvement of dyspnea was found in most patients of both groups. <h3>Conclusion</h3> Our results suggest that an early administration of ABA in RA-ILD may be preferable to preserve lung function. However, treatment with ABA at any time of the course in the ILD seems to prevent interstitial lung progression. <h3>References</h3> [1]Rheumatology. 2020 Dec 1;59(12):3906-3916 [2]Rheumatology. 2021 Dec 24;61(1):299-308 <b>Members of the Spanish Collaborative Group of ABA in RA-ILD:</b> L. Arboleya, J. Narváez, J. Carlos Fernández, Belén Miguel, Iván Cabezas, A. García Valle, C. Aguilera Cros, S. Romero-Yuste, I. Villa Blanco, S. Fernández Aguado, Raquel Almodóvar, C. Ojeda-García, C. Aguilera-Cros, B. García-Magallón, Antonio Juan Mas, M. J. Moreno-Ramos, A. Ruibal-Escribano, Rosa Expósito, José Antonio Bernal, Evelin C. Cervantes, S. Rodríguez-García, R. Castellanos-Moreira, Iván Castellví, Manuel Rodríguez, Eva Salgado, Enrique Raya, Pilar Morales, Lorena Expósito, Noelia Álvarez, José Luis Andreu, E. F. Vicente-Rabaneda, A. M. López-Robles, M. López-Corbeto, C. Hidalgo-Calleja, J.C. Fernández-López, Alejandro Olivé, S. Rodríguez-Muguruza, Iñigo Hernández, N. Quillis-Marti, J.A. Bernal-Vidal, A. García-Aparicio, S. Castro-Oreiro, J. Fernández-Melón, P. Vela Casasempere, María C. Fito, M. Rodríguez-Gómez, D. Palma-Sánchez, L. Expósito-Pérez, J. M. Andreu. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> Ana Serrano-Combarro: None declared, Belén Atienza-Mateo: None declared, N. Del-Val: None declared, Libe Ibarrola Paino: None declared, Ivette Casafont-Solé: None declared, Rafael Melero: None declared, Alba Pérez Linaza: None declared, Isabel Serrano-García: None declared, Santos Castañeda: None declared, Rafaela Ortega Castro: None declared, Jerusalem Calvo Gutierrez: None declared, Natalia Mena-Vázquez: None declared, Nuria Vegas-Revenga: None declared, Lucía Domínguez Casas: None declared, C. Delgado-Beltran: None declared, Carolina Díez: None declared, Trinidad Pérez Sandoval: None declared, M. Retuerto-Guerrero: None declared, Lorena Pérez Albaladejo: None declared, R. López-Sánchez: None declared, Mª Guadalupe Mazano: None declared, Anahy Brandy-Garcia: None declared, Patricia López Viejo: None declared, Gemma Bonilla: None declared, Olga Maiz: None declared, Maria del Carmen Carrasco Cubero: None declared, Marta Garijo Bufort: None declared, Mireia Moreno: None declared, ANA URRUTICOECHEA-ARANA: None declared, Sergi Ordoñez: None declared, C. González-Montagut Gómez: None declared, C. Peralta-Ginés: None declared, Maria Camila Osorio: None declared, Elena Cañadillas: None declared, Juan Ramón De Dios Jiménez de Aberásturi: None declared, Fernando Lozano Morillo: None declared, Tomas Vazquez Rodriguez: None declared, Patricia Carreira: None declared, J M Blanco: None declared, Carlos Fernández-Díaz: None declared, J. Loricera: None declared, Iván Ferraz-Amaro: None declared, Diego Ferrer: None declared, Ricardo Blanco Speakers bureau: Abbvie, Pfizer, Roche, lilly, Bristol-Myers, Janssen, Galapagos and MSD, Consultant of: Abbvie, Pfizer, Roche, lilly, Bristol-Myers, Janssen and MSD, Grant/research support from: Abbvie, MSD, novartis and Roche.